申请人:Liang Xifu
公开号:US20100279936A1
公开(公告)日:2010-11-04
The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C
1-10
heteroaryl, C
6-14
aryl or C
6-10
heterocycloalkylaryl; R
1
is C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
1-6
hydroxyalkyl, C
1-6
haloalkyl, C
1-6
amino, C
3-6
cycloalkyl, or C
1-6
heterocycloalkyl, each of which are optionally substituted; X represents —CR
3
R
4
—(CR
5
R
6
)
n
—(CR
7
═CR
8
)
m
—(C
6-14
aryl)
r
-(C
1-10
heteroaryl)
s
-(CR
9
R
10
)
p
—(CR
11
═CR
12
)
q
, R
2
represents C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
1-6
hydroxyalkyl, C
1-6
haloalkyl, C
1-6
amino, C
1-12
alkylsilyl, C
6-30
alkylarylsilyl, C
1-10
heteroaryl, C
6-14
aryl, C
1-10
heterocycloalkyl, C
1-10
heterocycloalkenyl, C
1-8
cycloalkyl, C
1-18
cycloalkenyl, each of which is optionally substituted, or R
2
represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.
该发明涉及新型化合物,其符合公式Ia和Ib;(公式Ia和Ib)其中A代表取代或未取代的C1-10杂环芳基,C6-14芳基或C6-10杂环烷基芳基; R1为C1-6烷基,C2-6烯基,C2-6炔基,C1-6羟基烷基,C1-6卤代烷基,C1-6氨基,C3-6环烷基或C1-6杂环烷基,每个基团都可以取代; X代表—CR3R4—(CR5R6)n—(CR7═CR8)m—(C6-14芳基)r-(C1-10杂环芳基)s-(CR9R10)p—(CR11═CR12)q,R2代表C1-6烷基,C2-6烯基,C2-6炔基,C1-6羟基烷基,C1-6卤代烷基,C1-6氨基,C1-12烷基硅烷基,C6-30烷基芳基硅烷基,C1-10杂环芳基,C6-14芳基,C1-10杂环烷基,C1-10杂环烯基,C1-8环烷基,C1-18环烯基,每个基团都可以取代,或R2代表氢,羧基或羟基;或其药学上可接受的盐,溶剂或酯;用于制备该化合物的工艺,以及用于治疗的化合物,包括该化合物的制药组合物,其中该化合物可用于治疗与CaSR活性紊乱有关的疾病,例如甲状旁腺功能亢进症。